Skip to main content
. 2023 Dec 14;130(3):417–424. doi: 10.1038/s41416-023-02514-5

Fig. 1. Study design.

Fig. 1

Chemonaive patients with advanced non small cell lung cancer (NSCLC) who presented with partial or complete response after platinum-based chemotherapy were randomized between placebo and olaparib. CR complete response, PD progessive disease, PR partial response, SD stable disease.